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Aims: To develop a clinically relevant, easy to use, and validated instrument for assessing severity and bother related to
urinary incontinence.Methods: Survey itemswere piloted and refined following psychometric principles in five separate
patient cohorts. Patient and expert endorsement of items, factor analyses, Spearman rank correlations and response
distributions were employed for item selection. Formal reliability and validity evaluation were conducted for the final
questionnaire items. Results: Expert physicians and patient focus groups confirmed face and content validity for the
measure. A 10-itemmeasure called theMichigan Incontinence Symptom Index (M-ISI)was developedwith two domains: a
TotalM-ISI Domain consisting of subdomains for stress urinary incontinence, urgency urinary incontinence, and pad use,
and a Bother Domain. High construct validity was demonstrated with a Cronbach’s alpha for the Total M-ISI Domain
(items 1-8) of 0.90 and for the Bother Domain (items 9-10) of 0.82. Cronbach’s alpha for the subdomains were all> 0.85.
Construct validity, convergent and divergent validity, internal discriminant validity, and predictive validity were all
robust. The minimally important difference for the measure was determined to be 4 points (out of 32) for the Total M-ISI
Severity Domain, and 1-2 points (out of 8-12) for the individual subdomains. Conclusions: The M-ISI is a parsimonious
measure that has established reliability and validity on several levels and complements current clinical evaluative
methods for patientswith urinary incontinence.Neurourol.Urodynam. 33:1128–1134, 2014.# 2013Wiley Periodicals, Inc.
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INTRODUCTION
Urinary incontinence (UI) is a highly prevalent condition
that affects both men and women across the age spectrum. It
is estimated that up to 13.9% of men and 51.1% of women
live with this condition,1 accounting for large direct and
indirect costs.2,3 In addition to being costly, UI has also been
shown to have a detrimental impact on quality of life, causing
men and women to alter their behaviors, to experience
psychological and emotional distress, and even to live in
social isolation.4–7
Despite being a common and costly condition, there is no
single good measurement tool currently available that can be
used to discern type, severity and bother attributable to UI.
Presently, in order to accomplish all of these goals, a patient
would have to complete multiple different questionnaires in
one sitting, and the physician would then have to determine
how to interpret and assimilate the results of these different
measures. For example, there are several measurement tools
that were specifically designed to evaluate quality of life in
women with UI; however, none of these tools are useful for
discerning type of urinary incontinence.8–13 Likewise, mea-
surement tools that were developed specifically to discern type
of UI, such as the Questionnaire for Urinary Incontinence
Diagnosis (QUID),14 are not equipped to evaluate quality of life
issues. The International Consultation on Incontinence Ques-
tionnaire (ICIQ), on the other hand, evaluates both quality of life
and type of urinary incontinence, but does not assimilate
severity with type of urinary incontinence.15 In addition to not
being comprehensive, these tools tend to be long, making them
difficult for patients to complete as part of the clinical
encounter. A simple measure that incorporates all of these
necessary components for diagnosing, treating, and following
UI over time is currently lacking.
The purpose of this study was to develop a parsimonious
measure that addresses all of these concerns. We used Classical
Test Theory in multiple patient populations to develop and
validate a measure that can discern type, severity, and bother
related to urinary incontinence. The productwas an instrument
called the Michigan Incontinence Symptom Index (M-ISI), that
has proven reliability and validity for use in both clinical and
research settings.
MATERIALS AND METHODS
Participants
There were 5 different participant groups used in the
development of the Michigan Incontinence Symptom Index:
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the focus, pilot, test-retest reliability, cross-sectional, and
predictive validity groups. Populations were recruited on an
as-needed basis to test newphases of instrument development.
The focus group consisted of 3 separate groups (2 female groups
and 1male group) comprised of a total of 26 women and 9men
with UI. These participants were recruited from local newspa-
per advertisements and from our institution’s urology clinics.
Subjects were prescreened to ensure that their UI was not due
to a secondary condition such as pregnancy, chronic urinary
tract infection, or bladder malignancy.
The pilot group consisted of male and female patients who
presented to the Urology clinic with a chief complaint of UI and
were recruited into the study. These subjects completed the M-
ISI at their initial clinic visit. A subset of these subjects also filled
out the M-ISI via a postal survey approximately 2–3 weeks
later, representing the test-retest reliability group. All subjects
were screened with a urinalysis and exclusionary criteria were
pregnancy, urinary tract infection, diagnosis of interstitial
cystitis or urinary retention, history of bladder malignancy,
presence of ureteral calculi and hematuria suspicious for
bladder malignancy.
The cross-sectional group consisted exclusively of women
who underwent surgery for UI at our institution. These women
were identified via administrative databases and invited to
participate in a questionnaire survey. Women with a history of
multiple sclerosis, spinal cord injury, urinary diversion, urethral
diverticula, urethrovaginal/vesicovaginal fistuals, or age <18
were excluded.16
The predictive validity group was made up of a convenience
sample of women aged 18 years or older who presented to our
institution’s multidisciplinary Urology/Urogynecology clinic
with a chief complaint of UI. Similar inclusion and exclusion
criteria to the pilot group were applied. Baseline evaluation
included a physical exam, urodynamic studies, and the M-ISI.
Based on the results of the baseline evaluation, the primary
type of UI was classified by the physician as either stress,
urgency or mixed. Patients were then treated per the
physicians’ usual clinical practice with surgery, medications,
behavioral therapy, combination therapy, or no treatment and
were assessed again at approximately 3 months post-treat-
ment with a repeat administration of the M-ISI.
Measures
Several existing questionnaires were administered to the
cross sectional group to establish both convergent and
divergent validity. Convergent validity was established by
comparing the M-ISI results with the results from Sandvik-
Hunskaar incontinence severity index and the incontinence
impact questionnaire (IIQ). Discriminant validity was estab-
lished using the 12-item short form health survey (SF-12) and
the pelvic organ prolapse/urinary incontinence sexual ques-
tionnaire (PISQ).
Sandvik-Hunskaar/incontinence severity index. The Sandvik-
Hunskaar severity index is a 2-item questionnaire that
classifies urinary incontinence based on frequency and amount
of urinary leakage into 4 categories (slight, moderate, severe,
and very severe). Scores range from 1 (slight) to 12 (very
severe).8 This indexwas validated against a 48 hour padweight
test for amount of leakage17 and a postal questionnaire survey
for severity of leakage.18
Incontinence Impact Questionnaire (IIQ). The IIQ is a 30-item
measure that assesses the impact of urinary incontinence on
various activities, roles, and emotional states. The IIQ has 4
subscales (physical activity, travel, social relationships, and
emotional health), including items that address shopping,
recreation, entertainment, and various feelings such as fear,
frustration, and anger. The patient responds to each item based
on the degree to which their urinary incontinence affects each
activity or feeling from not at all to greatly.9
Short-Form (SF-12) Health Survey. The SF-12 is a 12-item survey
that was reduced from the original 36-item health survey with
the use of regression methods. This measure asks questions
pertaining to general health related quality of life and consists
of 2 components, the Physical Components Summary (PCS) and
the Mental Components Summary (MCS). Each component is
scored on a scale with amean of 50 and a standard deviation of
10.19
Pelvic Organ Prolapse/Urinary Incontinence Sexual Question-
naire (PISQ). The PISQ is a 31 question measurement tool that
evaluates sexual function inwomenwith pelvic organ prolapse
and urinary incontinence. This measure includes 3 domains
(behavioral/emotive, physical, and partner-related) and uses 5-
value Likert-based scales (always to never) with the exception
of one question pertaining to masturbation.20
Procedures for scale development
Item selection for the M-ISI began with a thorough review of
the literature and of existing measures related to UI. An initial
list of 34 items was created with the specific aim of being able
to discern type [stress urinary incontinence (SUI), urgency
urinary incontinence (UUI), or both], severity and bother related
to UI. In summary, this list of items consisted of the following
distribution of topics: stress urinary incontinence, urgency
urinary incontinence, symptom severity/pad usage, other
urinary symptoms, and bother. These items were then
reviewed by content experts and focus groups for content
and face validity. Content experts consisted of urologists and
urogynecologists from across the United States who had
expertise in urinary incontinence (Appendix 1).
Using principles related to Classical Test Theory, the refined
list of items was administered to the pilot group. Exploratory
factor analysiswas performed to identify and establish discrete
domains and subdomains within M-ISI. Next, in order to
determine which items discriminated well between domains/
subdomains, factor loadingwas examined. Items that exhibited
major floor and ceiling effects were either reworded and
retested or removed. The final 10-item survey was then re-
administered to the pilot group and confirmatory factor
analysis was performed on the new data.
Statistical Analysis for Validation
Once the finalizedmeasurewas established, various aspects of
formal scale validation were performed in different study
populations. The cross-sectional group was used to determine
reliability and validity of theM-ISI. Cronbach’s alphawas used to
determine internal consistency of itemswithin subdomains and
domains of the instrument. Construct validitywas established in
the same cohort using Spearman rank correlations to show the
relationship between individual items with their scales.
Convergent and discriminant validity were established through
correlationwith othermeasures, namely the Sandvik-Hunskaar/
incontinence severity index and the IIQ for convergent validity
(measuring similar constructs, so desiring a high correlation) and
the SF-12 and PISQ for divergent validity (measuring alternative
constructs, so desiring lower correlations).
Test-retest reliability coefficients were calculated in a subset
of patients from the pilot group (the test-retest reliability
group). Predictive validity was established in the predictive
Incontinence Symptom Index 1129
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validity group by comparing the changes in themean scores for
the two domains of the M-ISI at baseline and at 3 months after
various treatments.
Next, a statistic to discern the predominant type of UI was
created and validated. This statistic is represented by the
following formula, which we will refer to as the Stress/
Urgency/Mixed (SUM) statistic: SUI subdomain score/[SUI
subdomain scoreþUUI subdomain score]. This statistic was
then compared to the physician’s (Dr. Edward J. McGuire)
classification of predominant SUI, predominant UUI, or
mixed UI using the predictive validity group. The physician’s
diagnosis was made based on clinical presentation and
history, physical examination, and urodynamics testing
when indicated. This statistic ranges from 0 to 1, with higher
scores representing predominant SUI, lower scores repre-
senting predominant UUI, and scores near 0.5 representing
mixed UI. If both SUI and UUI are equal to 0 (absence of both
Stress and Urgency Incontinence), then no statistic is
calculated.
The minimally important difference (MID) was determined
for the total ISI and bother domains and for the SUI and UUI
subdomains using both distribution- and anchor-based
methods21,22 based on data from the cross-sectional cohort.
Selected anchor measures included the Sandvik-Hunskaar/
incontinence severity index and the M-ISI Bother domain.
Distribution methods of MID (1/2 standard deviation and 1/3
standard deviation) were calculated by simple functions of
the standard deviation of the scores. Anchor-basedmethods of
the MID were calculated by regressing each of the M-ISI
domains and subdomains on the anchor item separately. The
MID for each anchor was determined by multiplying the
clinically relevant change in the anchor itemby the parameter
estimate from the regression for that item. The prospective
cohort was then used to assess the validity of the selectedMID
thresholds.
SAS statistical software version 9.2 (Cary, NC)was used for all
psychometric analyses.
RESULTS
The demographic characteristics of each of the 5 study groups
are presented in Table I.
Final Measure and Scoring
Item selection and refinement resulted in a 10-itemmeasure
that consists of a Total M-ISI Domain (sum of items 1-8) and a
distinct Bother Domain (sum of items 9-10), shown in Figure 1.
The Total M-ISI Domain consists of 3 subdomains (items 1-3 for
SUI, items 4-6 for UUI, and items 7-8 for Pad Use [PU]). All 10
items have Likert response options (range 0-4), with higher
values representing greater symptoms/bother. The Total M-ISI
Domain ranges from scores of 0 to 32, the Bother Domain
ranges from scores of 0 to 8, the SUI and UUI Subdomains range
from scores of 0 to 12, and the PU Subdomain ranges from
scores of 0-8. The overall domains and subdomains are scored
simply by summing their respective values. If any item in a
domain or a subdomain is missing, the domain/subdomain
score is not calculated. The only exception to this rule is for the
totalM-ISI scorewhen only a single item ismissing; in this case,
the missing item is assigned the mean of the 7 non-missing
items, and the domain score is summed as before.
Face Validity
Both participants from the focus groups and the content
experts reviewed and endorsed the final selection of items as
appropriate for urinary incontinence.
Construct, Convergent, and Discriminant Validity
Individual items of the M-ISI demonstrated both high
correlations with the Total Severity Domain and high correla-
tions with their respective subdomains while exhibiting lower
correlations with the other subdomains, indicating construct
validity (Table II). Correlations between the M-ISI and the
Sandvik-Hunskaar/incontinence severity index and the IIQ
were also high, indicating convergent validity, and low to
moderate correlations between the M-ISI and the SF-12 and
PISQ indicating divergent validity (Table III).
Predictive Validity
The relationship between the total M-ISI score and the
response to each of the bother items (adaptation [item 9] and
impairment [item10]) is shown in Figure 2. As scores for each of
TABLE I. Demographic characteristics of study cohorts
Focus group Pilot group Test-retest reliability group Cross-sectional group
Predictive
validity group
Development/Validation Phase Face
validity
Item selection Test-retest reliability Internal consistency Predictive validity
Exploratory factor analysis Construct validity SUM statistic
Factor loading Convergent validity
Discriminant validity
Minimally Important Difference
N 35 99 45 477 108
Female 26 64 32 477 108
Male 9 35 13 0 0
Median Age (range) 62 (32-81) 63.67 (23.56-91.27) -- 58.2 (21.3-91.7) 55.95 (27.16-87.81)
Actual therapies
Surgery -- -- -- 477 19 (17.6%)
Medications -- -- -- -- 11 (10.2%)
Behavioral therapy -- -- -- -- 11 (10.2%)
Combination therapy -- -- -- -- 9 (8.3%)
No treatment -- -- -- -- 58 (53.7%)
Test-retest reliability group is a subgroup of the pilot group
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Figure 1. Michigan Incontinence Symptom Index (M-ISI).
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the bother items increases (indicating a higher degree of
bother), the mean scores for the total M-ISI Domain also
increases, indicating good predictive validity.
Next, predictive validity of the change inmeanM-ISI scores in
response to various treatments was evaluated. Subjects
completed the M-ISI at baseline (prior to any treatment) and
at a mean of 3.5 months after treatment. Predictive validity of
the M-ISI was calculated by comparing mean changes in
domain scores from before to after different types of treatment.
Statistically significant changes in mean scores were found in
the Total M-ISI Domain for surgery, medication, and combina-
tion treatment, and in the Bother Domain for surgery and
behavioral treatment. The greatest improvements were seen in
the M-ISI scores for surgery.
Internal Discriminant Validity
Subjects who had a physician diagnosis of SUI had a mean
SUM statistic of 0.56, those with a physician diagnosis of UUI
had amean SUMstatistic of 0.32, and thosewithmixedUI had a
mean SUM statistic of 0.45, in between that for SUI and UUI.
Reliability/Internal Consistency
Cronbach’s alpha was high for each domains and subdo-
mains [Total M-ISI Domain (0.90), Bother Domain (0.82), SUI
Subdomain (0.87), UUI Subdomain (0.85), and PU Subdomain
(0.87)] indicating sufficient consistency of the scores.
Test-retest Reliability
Subjects in the test-retest reliability group completed the M-
ISI for a second time at amean of 18 days after taking the initial
survey. Test-retest reliability coefficients were calculated for
each domain and subdomain: Total M-ISI Domain (0.86), Bother
Domain (0.85), SUI Subdomain ((0.78), UUI Subdomain (0.78),
TABLE II. Spearman rank correlations within the M-ISI subdomains/domains. Analysis was performed using the cross-sectional cohort.
M-ISI Total Severity
Severity Subdomains
Bother SubdomainSUI UUI Pad use
Item 1 0.72 0.88 0.41 0.45 0.55
Item 2 0.73 0.89 0.48 0.39 0.57
Item 3 0.70 0.90 0.39 0.41 0.64
Item 4 0.82 0.49 0.91 0.53 0.61
Item 5 0.72 0.41 0.87 0.39 0.52
Item 6 0.68 0.39 0.83 0.41 0.59
Item 7 0.69 0.40 0.45 0.96 0.39
Item 8 0.73 0.48 0.47 0.93 0.49
Item 9 0.72 0.62 0.65 0.46 0.91
Item 10 0.66 0.58 0.56 0.43 0.93
SUI¼stress urinary incontinence, UUI¼urgency urinary incontinence
TABLE III. Convergent and discriminant validity of the M-ISI domains and subdomains to various other measurement scales measured by correlation
coefficients with corresponding p-values. Analysis was performed using the cross-sectional cohort.
SUI UUI PU Bother M-ISI Total
Convergent Validity
Sandvik severity measure 0.71 <.0001 0.80 <.0001 0.76 <.0001 0.73 <.0001 0.85 <.0001
IIQ Score 0.71 <.0001 0.66 <.0001 0.66 <.0001 0.85 <.0001 0.75 <.0001
Discriminant Validity
MCS12 0.07 0.16 0.12 0.01 0.08 0.11 0.18 0.0003 0.10 0.03
PCS12 0.39 <.0001 0.36 <.0001 0.36 <.0001 0.39 <.0001 0.41 <.0001
PISQ 0.44 <.0001 0.37 <.0001 0.43 <.0001 0.51 <.0001 0.46 <.0001
 SUI¼ stress urinary incontinence, UUI¼ urgency urinary incontinence, PU¼ pad use
Figure 2. Predictive validity of the Total M-ISI mean severity score to
response to bother items (adaptation and impairment). Analysis was
performed using the cross sectional group.
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and PU Subdomain (0.84), indicating sufficient reliability of the
scores.
Minimally Important Difference
Minimally important difference using distribution- and
anchor-based methods are shown in Appendix 2. These
analyses indicated narrow MID’s (i.e., fairly small changes in
scores for each subdomain/domain corresponded with a
clinically significant MID): 4 points for the total M-ISI domain
(out of 32 possible points); 2 points for the SUI subdomain (out
of 12 possible points); 2 points for the UUI subdomain (out of 12
possible points); and 1 point for the PU subdomain (out of 8
possible points).
DISCUSSION
TheM-ISI is a new 10-item questionnaire that was created to
be able to discern type (SUI, UUI, or both), severity and bother
attributable to UI. It is psychometrically robust and has proven
validity and reliability. It can be easily used in the clinical
setting to aid in the patient-physician encounter, establishing
the severity and nature of type of UI, and possesses the robust
psychometric criteria necessary for a research tool.
Unlike other UI questionnaires, the M-ISI covers different
aspects of UI that are essential for patient care and for research.
For example, there aremany questionnaires for UI that focus on
quality of life issues (including severity and impact), but that
neglect type of urinary incontinence. Some examples include
the King’s Health Questionnaire,12 the Symptom Severity Index
and the Symptom Impact Index,11 the Incontinence Quality of
Life (I-QOL) instrument,13 the Bristol Female Lower Urinary
Tract Symptoms questionnaire,10 the Incontinence Impact
Questionnaire (IIQ) and the Urogenital Distress Inventory
(UDI),9 and the Sandvik-Hunskaar/Incontinence Severity In-
dex.18 Questionnaires that do discern type of UI like the QUID;14
however, do not include items on quality of life. The
International Consultation on Incontinence Questionnaire
(ICIQ), developed by the International Consultation on Inconti-
nence (ICI), assesses the prevalence, frequency, perceived cause
of urinary incontinence, and impact on everyday life, but is not
proven to reliability discriminate type and severity attributable
to stress versus urgency urinary incontinence and does not
address pad usage.15 Another measure, the Female Urinary
Symptom Score (FUSS),23 was adapted from the International
Prostate Symptom Score to apply to female urinary inconti-
nence, is onlymeant to be used inwomen and does not address
pad usage. The M-ISI is unique in that it accomplishes all of
these goals, making it complete yet concise; a combination that
is ideal for both clinical and research purposes.
Althoughwe took a comprehensive approach to creating and
validating this instrument, this body of work is not without
limitations. First, the M-ISI has only been validated in English
thus far, but foreign language translations are anticipated.
Second, although the M-ISI was validated using cohorts that
included men, the number of men in these cohorts was small.
Furthermore, it is important to note that the M-ISI was not
formally validated for use in men. Third, we recognize that
women often experience symptoms of UUI as more severe and
more bothersome than symptoms of SUI,24 yet our measure
allocates an equal amount of weight to each type (i.e. 3
questions for each subdomain). This was done purposefully so
that the SUM statistic could be developed and be easily
interpreted. Finally, urinary incontinence can arise from many
other health conditions such as spinal cord injury or stroke; our
validation, to date, has not included these subpopulations. We
do intend to implement theM-ISI in these clinical subgroups in
the future.
CONCLUSIONS
The M-ISI is a clinically relevant, easy to use instrument that
is validated for urinary incontinence. It can be used both as a
clinical aid to facilitate physician-patient interactions and
delivery of care, and as a research tool to provide a level of
standardization and validity to UI outcome measurements.
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Appendix 2a
Distribution-based Minimally Important Difference for the M-
ISI. Scores are reported for the Total M-ISI, and SUI, UUI, and Pad
Use Domains and Subdomains. Analysis was performed using
the cross-sectional cohort.
Domain Possible Range
1/2 Standard
Deviation
1/3 Standard
Deviation
M-ISI Total Score 0–32 4.53 3.02
SUI 0–12 1.79 1.19
UUI 0–12 2.04 1.36
Pad Use 0–8 1.19 0.79
 SUI¼stress urinary incontinence, UUI¼urgency urinary
incontinence
Appendix 2b
Anchor-based Minimally Important Difference for the M-ISI.
Scores are reported for the totalM-ISI, and SUI, UUI, and PadUse
Domains and Subdomains. Analysis was performed using the
cross-sectional cohort.
Subdomain
Possible
Range
M-ISI Bother
Subdomain
(1 point increase)
Sandvik-Hunskaar
(2 point increase)
M-ISI Total Score 0–32 3.43 3.88
SUI 0–12 1.28 1.30
UUI 0–12 1.36 1.63
Pad Use 0–8 0.78 0.94
 SUI¼stress urinary incontinence, UUI¼urgency urinary
incontinence
 The Sandvik-Hunskaar and M-ISI bother subdomain were
used as anchor items
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